Treatments and Outcomes of Paget’s Sarcoma: Literature Review and Cohort Study

Article Sidebar

27-Sept-3204.pdf
Published Oct 31, 2022
DOI: https://doi.org/10.18103/mra.v10i10.3204

Downloads

Download data is not yet available.

Main Article Content

Santiago A. Lozano-Calderon Thomas Kennedy Joseph Werenski Alisha Sodhi Taylor McVeigh

Abstract

Background Sarcomatous transformation of Paget's disease of bone is a very rare, highly fatal complication. Isolated cohort studies have characterized these findings many times. Still, little has been established concerning the effects of patient and tumor characteristics and treatment type on the oncologic prognosis when defined as local recurrence-free, metastatic disease-free, disease-specific, and overall survival.


Questions/Purposes (1) What are the oncologic and clinical characteristics of patients who develop and are diagnosed with Paget’s sarcoma? (2) What are the outcomes when examining variables such as sarcoma type, presentation at diagnosis and treatment in Paget’s sarcoma patients? (3) How have treatment and oncologic prognosis changed in recent decades?


Methods A literature review of (n=1,001) Paget’s sarcoma cases, retrieved from previous studies and public databases, and a retrospective analysis on a cohort of all adult patients with Paget’s disease of bone (n=1,872) admitted to two large academic centers between 1979 and 2019 was performed. Medical records and the Social Security Index assessed patient survival. Surgical reports were reviewed to determine margin characteristics and intervention type. Incidences of metastasis and recurrence were based on patient notes and biopsy report review. This two-part study describes the effects of patient and tumor characteristics and treatment type on oncologic prognosis.


Results Pooled data from our literature review demonstrated a 5-year overall survival rate of 7.9%, in which patient age was significantly associated with worse survival prognosis (p=0.026). Treatment with surgery and adjuvant therapy was significantly associated with improved overall survival (p=0.006) compared to surgery alone or non-surgical treatment. Examining overall trends historically, neither presenting age nor survival appear to have a significant association with the year of diagnosis, demonstrating an R2 of 0.003 (p=0.48) for age at diagnosis and 0.023 (p=0.39) for survival from 1960 and 2016. From our retrospective cohort study, 32 out of 1,872 Paget’s patients were determined to have Paget’s sarcoma, indicating a prevalence of 1.7% for our database. The 5-year local recurrence-free, metastatic disease-free, disease-specific, and overall survival rates were 12.5%, 15.6%, 12.5%, and 18.8%, respectively. Patient age was significantly associated with worse survival outcomes (p=0.005) in our institutions’ patient registry. 


Conclusion Including over 1,000 Paget's sarcoma patients in our study greatly strengthens the associations between treatment type and survival. While patients undergoing multimodal therapy reported the greatest longevity, concerns remain for mobility and quality of life. Our cohort study indicates that few factors can effectively predict oncologic outcomes for Paget's sarcoma patients. Age is the strongest underlying factor for poor prognosis. Patient outcomes have not changed significantly in the last 80 years; our literature and cohort study highlights the need for increased clinician awareness and improved treatment modalities for Paget's sarcoma.


Level of Evidence Level III, retrospective comparative study and review of other level III studies.

Article Details

How to Cite
LOZANO-CALDERON, Santiago A. et al. Treatments and Outcomes of Paget’s Sarcoma: Literature Review and Cohort Study. Medical Research Archives, [S.l.], v. 10, n. 10, oct. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3204>. Date accessed: 18 apr. 2024. doi: https://doi.org/10.18103/mra.v10i10.3204.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 10 No 10 (2022): October issue VOl.10 Issue 10
Section
Review Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Barry, H. C. (1960). Sarcoma in Paget's disease of bone. Australian and New Zealand Journal of Surgery, 29(4), 304-310.
2. Crisp, A. J. (1993). Pathophysiology and treatment of Paget's disease of bone. Annals of the rheumatic diseases, 52(2), 92.
3. Delmas, P. D., & Meunier, P. J. (1997). The management of Paget's disease of bone. New England Journal of Medicine, 336(8), 558-566.
4. Deyrup, A. T., Montag, A. G., Inwards, C. Y., Xu, Z., Swee, R. G., & Krishnan Unni, K. (2007). Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Archives of pathology & laboratory medicine, 131(6), 942-946.
5. Dray, M. S., & Miller, M. V. (2008). Paget's osteosarcoma and post-radiation osteosarcoma: secondary osteosarcoma at Middlemore Hospital, New Zealand. Pathology, 40(6), 604-610.
6. Enneking, W. F., Spanier, S. S., & Goodman, M. A. (1980). A system for the surgical staging of musculoskeletal sarcoma. Clinical Orthopaedics and Related Research (1976-2007), 153, 106-120.
7. Frassica, F. J., Sim, F. H., Frassica, D. A., & Wold, L. E. (1991). Survival and management considerations in postirradiation osteosarcoma and Paget's osteosarcoma. Clinical orthopaedics and related research, (270), 120-127.
8. Greditzer 3rd, H. G., McLeod, R. A., Unni, K., & Beabout, J. W. (1983). Bone sarcomas in Paget disease. Radiology, 146(2), 327-333.
9. Hadjipavlou, A., Lander, P., Srolovitz, H., & Enker, I. P. (1992). Malignant transformation in Paget disease of bone. Cancer, 70(12), 2802-2808.
10. Haibach H, Farrell C, Dittrich FJ. Neoplasms arising in Paget’s disease of bone: a study of 89 cases. A m / Clin Pathol 1985; 83~594-600.
11. Huvos, A. G. (1986). Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer, 57(7), 1442-1449.
12. Huvos, A. G., Butler, A., & Bretsky, S. S. (1983). Osteogenic sarcoma associated with Paget's disease of bone. A clinicopathologic study of 65 patients. Cancer, 52(8), 1489-1495.
13. LeBoff, M. S., & Lane, N. (1997). Metabolic bone disease. Textbook of rheumatology, 2, 1574-80.
14. Mangham, D. C., Davie, M. W., & Grimer, R. J. (2009). Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation. Bone, 44(3), 431-436.
15. Mankin, H. J., & Hornicek, F. J. (2005). Paget’s sarcoma: a historical and outcome review. Clinical Orthopaedics and Related Research®, 438, 97-102.
16. McKenna, R. J., & Schwinn, C. P. (1964). SOONG, KY, and HIGINBOTHAM. NL Osteogenic sarcoma arising in Paget’s disease. Cancer, 17, 42-65.
17. Mirabello, L., Troisi, R. J., & Savage, S. A. (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer: Interdisciplinary International Journal of the American Cancer Society, 115(7), 1531-1543.
18. Moore, T. E., King, A. R., Kathol, M. H., El-Khoury, G. Y., Palmer, R., & Downey, P. R. (1991). Sarcoma in Paget disease of bone: clinical, radiologic, and pathologic features in 22 cases. AJR. American journal of roentgenology, 156(6), 1199-1203.
19. Paget J 1889 Remarks on osteitis deformans. Illustr Med News 2:181–182.
20. Paul Tuck, S., Layfield, R., Walker, J., Mekkayil, B., & Francis, R. (2017). Adult Paget’s disease of bone: a review. Rheumatology, 56(12), 2050-2059.
21. Porretta CA, Dahlin DC, Janes JM.Sarcoma in Paget’s disease of bone. J Bone Joint Surg 1957; 39-A:1314-29.
22. Price, C. H. G., & Goldie, W. (1969). Paget's sarcoma of bone: a study of eighty cases from the Bristol and the Leeds bone tumour registries. The Journal of Bone and Joint Surgery. British volume, 51(2), 205-224.
23. Ralston, S. H., Langston, A. L., & Reid, I. R. (2008). Pathogenesis and management of Paget's disease of bone. The Lancet, 372(9633), 155-163.
24. Rosen, C. J., Compston, J. E., & Lian, J. B. (2009). ASBMR primer on the metabolic bone diseases and disorders of mineral metabolism. John Wiley & Sons.
25. Ruggieri, P., Calabrò, T., Montalti, M., & Mercuri, M. (2010). The role of surgery and adjuvants to survival in Pagetic osteosarcoma. Clinical Orthopaedics and Related Research®, 468(11), 2962-2968.
26. Russell, W. O., Cohen, J., Enzinger, F., Hajdu, S. I., Heise, H., Martin, R. G., ... & Suit, H. D. (1977). A clinical and pathological staging system for soft tissue sarcomas. Cancer, 40(4), 1562-1570.
27. Schajowicz, F., Santini Araujo, E., & Berenstein, M. (1983). Sarcoma complicating Paget's disease of bone. A clinicopathological study of 62 cases. The Journal of bone and joint surgery. British volume, 65(3), 299-307.
28. Seitz, S., Priemel, M., Zustin, J., Beil, F. T., Semler, J., Minne, H., ... & Amling, M. (2009). Paget's disease of bone: histologic analysis of 754 patients. Journal of Bone and Mineral Research, 24(1), 62-69.
29. Seret, P., Basle, M. F., Rebel, A., Renier, J. C., Saint-Andre, J. P., Bertrans, G., & Audran, M. (1987). Sarcomatous degeneration in Paget's bone disease. Journal of cancer research and clinical oncology, 113(4), 392-399.
30. Sharma, H., Jane, M. J., & Reid, R. (2005). Scapulo‐humeral Paget's sarcoma: Scottish Bone Tumour Registry experience. European journal of cancer care, 14(4), 367-372.
31. Sharma, H., Mehdi, S. A., MacDuff, E., Reece, A. T., Jane, M. J., & Reid, R. (2006). Paget sarcoma of the spine: Scottish Bone Tumor Registry experience. Spine, 31(12), 1344-1350.
32. Shaylor, P. J., Peake, D., Grimer, R. J., Carter, S. R., Tillman, R. M., & Spooner, D. (1999). Paget's osteosarcoma—no cure in sight. Sarcoma, 3(3-4), 191-192.
33. Singer, F. (2016). Paget’s disease of bone. In Endotext [Internet]. MDText. com, Inc..
34. Siris, E. S., Lyles, K. W., Singer, F. R., & Meunier, P. J. (2006). Medical management of Paget's disease of bone: indications for treatment and review of current therapies. Journal of Bone and Mineral Research, 21(S2), P94-P98.
35. Smith J, Botet JF, Yeh SDJ. Bone sarcoma in Paget’s disease: a study of 85 patients. Radiology 1984; 152:583-90.
36. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 9 Registries, Nov 2019 Sub (1975-2017) - Linked To County Attributes - Time Dependent (1990-2017) Income/Rurality, 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission.
37. Van Staa, T. P., Selby, P., Leufkens, H. G. M., Lyles, K., Sprafka, J. M., & Cooper, C. (2002). Incidence and natural history of Paget's disease of bone in England and Wales. Journal of Bone and Mineral Research, 17(3), 465-471.
38. Whyte, M. P. (2006). Paget's disease of bone. New England Journal of Medicine, 355(6), 593-600.
39. Wick, M. R., Siegal, G. P., Unni, K. K., & McLeod, R. A. (1981). Sarcomas of bone complicating osteitis deformans (Paget's disease): fifty years' experience. The American journal of surgical pathology, 5(1), 47-59.
40. Hocking L.J., Lucas G.J.A., Daroszewska A., et. al. (2004). Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res, 19, 1122-1127.
41. Chung P.Y., Beyens G., Guañabens N., et. al. (2008). Founder effect in different European countries for the recurrent P392L SQSTM1 mutation in Paget’s disease of bone. Calcif Tissue Int 83, 34-42.
42. Friedrichs W.E., Reddy S.V., Bruder J.M., et. al. (2002). Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res 17,145-151.
43. Mee A.P., Dixon J.A., Hoyland J.A., et. al. (1998). Detection of canine distemper virus in 100% of Paget’s disease samples by in situ-reverse transcriptase-polymerase chain reaction. Bone, 23, 171-175.
44. Matthews B.G., Afzal M.A., Minor P.D. (2008). Failure to detect measles virus RNA in bone cells from patients with Paget's disease. J Clin Endocrinol Metab, 93, 1398-1401.
45. Ralston S.H., Afzal M.A., Helfrich M.H., et. al. (2007). Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget's disease of bone. J Bone Miner Res, 22, 569-577.
46. Reid I.R., Davidson J.S., Wattie D., et. al. (2004). Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone, 35, 224-230.
47. Merlotti D., Gennari L., Martini G., et. al. (2009). Current options for the treatment of Paget’s disease of the bone. Open Access Rheumatol Res Rev, 1, 108-120.
48. Langston A.L., Campbell M.K., Fraser W.D., et. al. (2010). Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res, 25, 20-31.
49. Al-Rashid, M., Ramkumar, D., Raskin, K., Schwab, J., Hornicek, F.J., & Lozanó-Calderon, S.A. (2015). Paget Disease of Bone. Orthopedic Clinics of North America, 46(4), 577-585.